Fevipiprant demonstrates novel anti-inflammatory effects on blood and airway gene expression in patients with persistent eosinophillic asthma

13:00 - 13:06

Speaker: David Sandham

Fevipiprant inhibits prostaglandalin D2 mediated activation og group 2 innate lymphoid cells (ILC2s)

13:06 - 13:12

Speaker: David Sandham

Fevipiprant, a potent selective antagonist of the prostaglandin D2 receptor 2, modulates the allergic effector unit via inhibition of eosinophil migration towards mast cells

13:12 - 13:18

Speaker: David Sandham

Fevipiprant, a potent selective prostaglandin D2 receptor 2 (DP2) antagonist, dose-dependently inhibits pulmonary inflammation in a mouse model of asthma

13:18 - 13:24

Speaker: David Sandham

Exploring the potential role of the calcium-sensing receptor in a house dust mite model of allergic airway disease

13:24 - 13:30

Speaker: Jiayin Diao

Forced expiratory flow as an alternative paediatric lung function measurement

13:30 - 13:36

Speaker: Benjamin Van Hecke

The man who'd never seen a doctor

13:36 - 13:42

Speaker: Eric Douglas

The use of eucapnic voluntary hyperventilation as a bronchoprovocation technique for exercise induced bronchoconstriction in the clinical setting

13:42 - 13:48

Speaker: Su Wei Khung

Persistent airflow limitation in severe asthma - remodeling or uncontrolled inflammation

13:48 - 13:54

Speaker: Naomi Watson